EyePoint, Inc. develops and commercializes therapeutics for retinal diseases using its proprietary bioerodible Durasert E technology platform, which enables sustained intraocular drug delivery. The company's lead product candidate, DURAVYU, combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert E delivery system and is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The pipeline also includes EYP-2301, a TIE-2 agonist in preclinical development formulated with Durasert E for serious retinal diseases.
The company operates as a clinical-stage biotechnology firm with 165 full-time employees based in Watertown, Massachusetts. EyePoint is publicly traded on Nasdaq and was incorporated in Delaware in 1987, undergoing a name change from EyePoint Pharmaceuticals, Inc. in December 2025. The company's revenue streams and business segments are not separately disclosed, as development programs remain in clinical evaluation phases prior to potential commercialization.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.32 | $-2.32 | -27.5% | |
| 2023 | $-1.82 | $-1.82 | +33.6% | |
| 2022 | $-2.74 | $-2.74 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | $-0.52 | $-0.52 | +23.5% | |
| 2016 | $-0.68 | $-0.68 | -300.0% | |
| 2015 | $-0.17 | $-0.17 | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | $-1.19 | $-1.19 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-06 | 0000950170-25-034601 | SEC ↗ |
| 2023-12-31 | 2024-03-08 | 0000950170-24-028523 | SEC ↗ |
| 2022-12-31 | 2023-03-10 | 0000950170-23-007180 | SEC ↗ |
| 2021-12-31 | 2022-03-14 | 0001564590-22-009929 | SEC ↗ |
| 2020-12-31 | 2021-03-12 | 0001564590-21-012894 | SEC ↗ |
| 2019-12-31 | 2020-03-16 | 0001564590-20-010956 | SEC ↗ |
| 2018-06-30 | 2018-09-18 | 0001193125-18-276414 | SEC ↗ |
| 2017-06-30 | 2017-09-13 | 0001193125-17-283875 | SEC ↗ |
| 2016-06-30 | 2016-09-13 | 0001193125-16-708358 | SEC ↗ |
| 2015-06-30 | 2015-09-10 | 0001193125-15-316983 | SEC ↗ |
| 2014-06-30 | 2014-09-11 | 0001193125-14-338993 | SEC ↗ |
| 2013-06-30 | 2013-09-27 | 0001193125-13-382009 | SEC ↗ |
| 2012-06-30 | 2012-09-27 | 0001193125-12-406956 | SEC ↗ |
| 2011-06-30 | 2011-09-13 | 0001193125-11-246966 | SEC ↗ |
| 2010-06-30 | 2010-09-27 | 0001193125-10-217638 | SEC ↗ |
| 2009-06-30 | 2009-09-25 | 0001193125-09-198276 | SEC ↗ |
| 2008-06-30 | 2008-09-26 | 0001193125-08-202144 | SEC ↗ |